Aptamer Group PLC · LSE:APTA
Aptamer — ShareSoc Growth Company Seminar 2025
17 slides from Aptamer's conference presentation, October 2025
Slide 1: ShareSoc Growth Company Seminar
ShareSoc Growth Company Seminar [email protected] www.aptamergroup.com
Slide 2: Disclaimer
© Aptamer Group 2025 DISCLAIMER This presentation (“Presentation”) contains forward-looking statements, including in relation to the financial position and prospects of Aptamer Group plc (“Company”) and its group (“Group”). These forward-looking statements are not based on historical facts but rathe
Slide 3: Board of Directors and Presentation team
© Aptamer Group 2025 Board of Directors and Presentation team Presentation Dr Adam Hargreaves team Non-Exec Chair Dr Arron Tolley Andrew Rapson Chief Executive Chief Financial Officer Officer Dr David Bunka Chief Scientific Officer ‒ Co-founded Aptamer Group in 2008 ‒ Over 20 years of finance experi
Slide 4: Business overview
© Aptamer Group 2025 Business overview Recognised as a key global player in aptamer development 1 Business overview Operating in a $210 billion affinity ligand market 2 - Incorporated in 2008 - Headquartered in York, UK Relationships with all the Top 10 global pharma companies 3 - AIM IPO in Dec 202
Slide 5: A need for new binder technology
© Aptamer Group 2025 A need for new binder technology Less than 50% of commercially available antibodies are functional resulting in annual losses >$800 million.1,2 Aptamer Traditional binders, such as antibodies, Optimer® offers Group’s journey require animals or cell-based systems to discover, dev
Slide 6: Aptamer Group's journey from basement to market
© Aptamer Group 2025 Aptamer Group’s journey from basement to market Platform technology model Solving problems Doubling revenue year on year till IPO. 2010 2016 2021 Aptamer Group’s journey 6
Slide 7: Technical advantages of our platform
© Aptamer Group 2025 Technical advantages of our platform Optimer® technology Broad target applicability - highly selective binders for small molecules, proteins and cell overview targets Tuneable selectivity that is tailored to the user’s end application Synthetic manufacture allows better quality
Slide 8: Our technology and its fit in the market
© Aptamer Group 2025 Our technology and its fit in the market Less than 50% of commercially available antibodies are functional resulting in annual losses >$800 million.1,2 Our platforms are engineered to address the need for new affinity ligands. We are operating in a $210 billion affinity ligand m
Slide 9: Developing Optimers to targets antibodies can't reach
© Aptamer Group 2025 Developing Optimers to targets antibodies can’t reach Folic acid (vitamin B9) plays a crucial role in red blood cell production and helps prevent serious birth defects, such as spina bifida. Alternative binding technologies are not flexible enough to specifically recognize small
Slide 10: Programming function for enzyme modulation
© Aptamer Group 2025 Programming function for enzyme modulation Different functions can be programmed into Optimers to meet specific needs. For modifying enzyme function, this involves 3 stages of: Step 1: Optimer® specifically binds to enzyme Optimer® can specifically inhibit or promote enzyme func
Slide 11: Exquisite specificity to solve gene therapy's targeting challenge
© Aptamer Group 2025 Exquisite specificity to solve gene therapy’s targeting challenge Targeting gene therapies to specific tissues for safer drugs is a limiting factor in bringing new treatments to patients in need. Optimer® offers tuned targeting for specific tissues to enable new precision gene t
Slide 12: A diverse and partnered asset portfolio
© Aptamer Group 2025 A diverse and partnered asset portfolio Genetic medicine company Expanded licensing pipeline from 4 to 11 active negotiations over the last year. Top 5 Internal R&D pharma Assay portfolio split across different life science segments consisting of short-, medium-, and long- term
Slide 13: Commercial progression of Optimer assets
© Aptamer Group 2025 Commercial progression of Optimer® assets Two royalty-bearing licenses agreed for current assets, offering ongoing, non-dilutive revenue streams. • A royalty agreement with Neuro-Bio on sales of Optimer® -based clinical diagnostics for Alzheimer’s disease with a blended royalty
Slide 14: Revenue growth and financial position
© Aptamer Group 2025 Revenue growth and financial position Unaudited revenue for Cash position at year Post-period fundraise Strengthened financial FY25 £1.20 million end £1.06 million of £1.82 million position to execute (FY24: £0.85 million) - (net expenses) planned development 41% increase progra
Slide 15: Use of funds
© Aptamer Group 2025 Use of funds £1.8 million raised in July to accelerate the commercialisation of Optimer® technology and advance licensing. Asset licensing Manufacturing investment negotiations Advancing liver fibrosis programme Commercial review Biomarker discovery AI & machine learning service
Slide 16: Investment case
© Aptamer Group 2025 Investment case Optimer® for deodorant Alzheimer’s diagnostic Drug delivery vehicles with with Unilever with NeuroBio AstraZeneca Fee-for-service arm targeting 02 the $210bn affinity ligand Developing high-value assets with strategic partners market1 to meet demand for to target
Slide 17: Contact
E: [email protected] W: aptamergroup.com